Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice

Cancer Research

Volumn 72, Issue 19, 2012, Pages 4931-4943

  Wong, Karrie K ^a,b   Brenneman, Fred ^d   Chesney, Alden ^d   Spaner, David E ^c,e   Gorczynski, Reginald M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Research Institute   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD200; OKT 3; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CELL GROWTH; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN CELL; TUMOR XENOGRAFT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; MUROMONAB-CD3; SPLEEN; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 84867136378     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1390     Document Type: Article

References (44)

1. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008;29:464-8.
2. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194 -7.
3. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007;117:3922-9. (Pubitemid 350224101)
4. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008;57:987-96.
5. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, et al. CD200 as a prognostic factor in acutemyeloid leukaemia. Leukemia 2007;21:566-8.
6. Wong KK, Khatri I, Shaha S, Spaner DE, Gorczynski RM. The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010;88:361-72.
7. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
8. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-74.
9. Mainou-Fowler T, Miller S, Proctor SJ, Dickinson AM. The levels of TNF alpha, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia Res 2001;25:157-63. (Pubitemid 32141119)
10. Mainou-Fowler T, Proctor SJ, Miller S, Dickinson AM. Expression and production of interleukin 4 in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2001;42:689-98. (Pubitemid 32782777)
11. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-88. (Pubitemid 38145555)
12. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
13. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005;115:1797-805. (Pubitemid 40979718)
14. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-37. (Pubitemid 351949771)
15. Seiffert M, Schulz A, Ohl S, Dohner H, Stilgenbauer S, Lichter P. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo . Blood 2011;116:4223-30.
16. Eisterer W, Bechter O, Soderberg O, Nilsson K, Terol M, Greil R, et al. Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res 2004;28:1043-51. (Pubitemid 39037337)
17. Brizard A, Morel F, Lecron JC, Dreyfus B, Brizard F, Barra A, et al. Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23. Leuk Lymphoma 1994;14:311- 8.
18. Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res 2007;67:1823-31. (Pubitemid 46383409)
19. Chen DX, Gorczynski RM. Discrete monoclonal antibodies define functionally important epitopes in the CD200 molecule responsible for immunosuppression function. Transplantation 2005;79:282-8. (Pubitemid 40299533)
20. Gorczynski RM. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 2005;6:483-8. (Pubitemid 40613969)
21. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56.
22. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009;23:25-47.
23. Garton KJ, Gough PJ, Raines EW. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 2006;79:1105-16. (Pubitemid 44835543)
24. Hummel JL, Lichty BD, Reis M, Dube I, Kamel-Reid S. Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia 1996;10:1370-6. (Pubitemid 26261438)
25. Marcus H, Shimoni A, Ergas D, Canaan A, Dekel B, Ben-David D, et al. Human/mouse radiation chimera generated from PBMC of B chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce anti-human red cell antibodies. Leukemia 1997;11:687-93. (Pubitemid 27241248)
26. Ruchlemer R, Wotherspoon AC, Thompson JN, Swansbury JG, Matutes E, Catovsky D. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia. Br J Haematol 2002;118:952-8. (Pubitemid 35025956)
27. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002;99:1030-7. (Pubitemid 34525568)
28. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol 2006;37:152-9. (Pubitemid 43099834)
29. Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM. Mice lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 2007;84:251-7. (Pubitemid 47205760)
30. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res 2011;23:133-43.
31. Gorczynski RM, Chen Z, Hu J, Kai Y, Lei J. Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice. Clin Exp Immunol 2001;126:220-9. (Pubitemid 32995135)
32. Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K, et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat 2010;123:405-15.
33. Di Giovanni S, Valentini G, Carducci P, Giallonardo P. Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 1989;81:181-5. (Pubitemid 19186451)
34. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439-47. (Pubitemid 26341010)
35. Bertilaccio MT, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, et al. A novel Rag2-/-gammac-/--xenograft model of human CLL.Blood 2010;115:1605-9.
36. Durig J, Ebeling P, Grabellus F, Sorg UR, Mollmann M, Schutt P, et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007;67:8653-61. (Pubitemid 47437441)
37. Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, et al. Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow. Cancer Res 2009;69:3121-30.
38. Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, et al. Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res 2005;29:1347-52. (Pubitemid 41297648)
39. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118:281-92.
40. Sawicka-Powierza J, Jablonska E, Kloczko J, Piszcz J, Garley M, Ratajczk-Wrona W. Evaluation of TNF superfamily molecules release by neutrophils and B leukemic cells of patients with chronic B-cell lymphocytic leukemia. Neoplasma 2011;58:45-50.
41. Mellstedt H, Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. Cancer Immunol Immunother 2006;55:210-20.
42. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-9. (Pubitemid 36118829)
43. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011;117:5463-72.
44. Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 2008;3:22-30. (Pubitemid 351276813)